Adipotide

Description

What is Adipotide?

Adipotide (FTPP) is a synthetic peptide. It is evaluated in experimental models for its interaction with vascular markers associated with adipose tissue compartments.

How does Adipotide work?

Adipotide has been investigated in preclinical experimental models for its affinity toward vascular-associated surface receptors. These receptors are expressed in adipose-related tissue systems.

In controlled analytical studies, peptide-receptor interaction has been associated with modulation of vascular functionality parameters.

Research Applications of Adipotide

Current analytical investigations on Adipotide have focused on:

• Apoptosis-Related Signaling Pathways:

Laboratory studies evaluating programmed cell signaling responses following peptide-receptor interaction in controlled systems.

• Metabolic Biomarker Analysis:

Preclinical investigations exploring changes in metabolic-related biomarker indices under structured experimental conditions.

These applications remain limited to controlled laboratory and preclinical research models. Further structured analytical studies are required to expand mechanistic understanding.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human usage.

Reference Links

• (2026). Clinicaltrials.gov. https://clinicaltrials.gov/study/NCT01262664
• Arrowhead Announces FDA Clearance to Initiate AdipotideTM Phase I Clinical Trial - Arrowhead Pharmaceuticals, Inc. (2026). Arrowhead Pharmaceuticals, Inc. https://arrowheadpharma.com/news-press/arrowhead-announces-fda-clearance-to-initiate-adipotide-phase-i-clinical-trial/

• Author, F. B. (2012, July 20). Arrowhead Announces Dosing of First Patient with Anti-Obesity Treatment Adipotide® in a Phase 1 Clinical Trial. Fierce Biotech.https://www.fiercebiotech.com/biotech/arrowhead-announces-dosing-of-first-patient-anti-obesity-treatment-adipotide%C2%AE-a-phase-1

About Team PureRawz

Team PureRawz is dedicated to providing accurate, science-based information on research chemicals, including Peptides, Nootropics, and SARMs. Our team of expert writers, researchers, and editors is committed to delivering reliable, up-to-date content you can trust.

Our mission is to build an educated and informed community spanning researchers, laboratories, and general readers empowering them to make confident, well-informed decisions when selecting the right research chemical.

View Full Profile →